Forest licenses US marketing rights to Merz compound
Forest Laboratories has acquired US marketing and development rights toa glutamate NMDA receptor antagonist, neramexane, originated by German firm Merz+Co. Neramexane will be investigated in Phase II studies for a broad range of possible indications. This is the second product in this class that Forest has licensed from Merz after memantine, a drug which is marketed for Alzheimer's disease in Germany. Forest is developing it in the USA for AD and neuropathic pain (Marketletter July 10, 2000), and the firm said it expects to file a New Drug Application for the AD indication for memantine this fiscal year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze